VIRI vs. CVKD, TRVN, BNOX, NCNA, BFRI, CYCN, VCNX, EFTR, HEPA, and UPC
Should you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include Cadrenal Therapeutics (CVKD), Trevena (TRVN), Bionomics (BNOX), NuCana (NCNA), Biofrontera (BFRI), Cyclerion Therapeutics (CYCN), Vaccinex (VCNX), eFFECTOR Therapeutics (EFTR), Hepion Pharmaceuticals (HEPA), and Universe Pharmaceuticals (UPC). These companies are all part of the "pharmaceutical preparations" industry.
Cadrenal Therapeutics (NASDAQ:CVKD) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, community ranking, profitability, earnings, dividends and risk.
Cadrenal Therapeutics has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500.
Virios Therapeutics is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.
Virios Therapeutics' return on equity of -75.11% beat Cadrenal Therapeutics' return on equity.
7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 58.1% of Cadrenal Therapeutics shares are held by company insiders. Comparatively, 11.7% of Virios Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Cadrenal Therapeutics received 2 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave Cadrenal Therapeutics an outperform vote while only 66.67% of users gave Virios Therapeutics an outperform vote.
Cadrenal Therapeutics currently has a consensus target price of $3.50, suggesting a potential upside of 694.55%. Given Virios Therapeutics' higher possible upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Virios Therapeutics.
In the previous week, Virios Therapeutics had 4 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 12 mentions for Virios Therapeutics and 8 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.59 beat Virios Therapeutics' score of 0.35 indicating that Virios Therapeutics is being referred to more favorably in the news media.
Summary
Cadrenal Therapeutics beats Virios Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Virios Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Virios Therapeutics Competitors List
Related Companies and Tools
